NO20082695L - 3-(4-{[4-(4-{[3-(3,3-dimetyl-1-piperidinyl)propyl]oksy}fenyl)-1-piperidinyl]-karbonyl}-1-naftalenyl)propan- eller propensyre som H1 og H3 reseptorantagonister for behandling av betennelser og/eller allergiske lidelser - Google Patents
3-(4-{[4-(4-{[3-(3,3-dimetyl-1-piperidinyl)propyl]oksy}fenyl)-1-piperidinyl]-karbonyl}-1-naftalenyl)propan- eller propensyre som H1 og H3 reseptorantagonister for behandling av betennelser og/eller allergiske lidelserInfo
- Publication number
- NO20082695L NO20082695L NO20082695A NO20082695A NO20082695L NO 20082695 L NO20082695 L NO 20082695L NO 20082695 A NO20082695 A NO 20082695A NO 20082695 A NO20082695 A NO 20082695A NO 20082695 L NO20082695 L NO 20082695L
- Authority
- NO
- Norway
- Prior art keywords
- piperidinyl
- treatment
- naphthalenyl
- oxy
- inflammation
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 title 2
- -1 3- (4 - {[4- (4 - {[3- (3,3-Dimethyl-1-piperidinyl) propyl] oxy} phenyl) -1-piperidinyl] carbonyl} -1-naphthalenyl) propane Chemical compound 0.000 title 1
- 102000003834 Histamine H1 Receptors Human genes 0.000 title 1
- 108090000110 Histamine H1 Receptors Proteins 0.000 title 1
- 102000004384 Histamine H3 receptors Human genes 0.000 title 1
- 108090000981 Histamine H3 receptors Proteins 0.000 title 1
- 206010061218 Inflammation Diseases 0.000 title 1
- 230000000172 allergic effect Effects 0.000 title 1
- 208000010668 atopic eczema Diseases 0.000 title 1
- 208000035475 disorder Diseases 0.000 title 1
- 230000004054 inflammatory process Effects 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 238000002360 preparation method Methods 0.000 abstract 2
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0525897A GB0525897D0 (en) | 2005-12-20 | 2005-12-20 | Compounds |
| GB0623217A GB0623217D0 (en) | 2006-11-21 | 2006-11-21 | Compounds |
| PCT/EP2006/069943 WO2007071691A1 (en) | 2005-12-20 | 2006-12-19 | 3- (4-{ [4-(4-{ [3-(3, 3-dimethyl-1-piperidinyl) propyl] 0xy} phenyl) -1-piperidinyl] carbonyl }-1-naphthalenyl) propanoic or propenoic acid as h1 and h3 receptor antagonists for the treatment of inflammatory and/or allergic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20082695L true NO20082695L (no) | 2008-09-16 |
Family
ID=37845266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20082695A NO20082695L (no) | 2005-12-20 | 2008-06-11 | 3-(4-{[4-(4-{[3-(3,3-dimetyl-1-piperidinyl)propyl]oksy}fenyl)-1-piperidinyl]-karbonyl}-1-naftalenyl)propan- eller propensyre som H1 og H3 reseptorantagonister for behandling av betennelser og/eller allergiske lidelser |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US7989629B2 (pl) |
| EP (2) | EP2157087A1 (pl) |
| JP (2) | JP4445570B2 (pl) |
| KR (1) | KR20080087102A (pl) |
| AR (1) | AR058109A1 (pl) |
| AT (1) | ATE449769T1 (pl) |
| AU (1) | AU2006328512B2 (pl) |
| BR (1) | BRPI0620218A2 (pl) |
| CA (1) | CA2634391A1 (pl) |
| CR (1) | CR10102A (pl) |
| CY (1) | CY1110601T1 (pl) |
| DE (1) | DE602006010737D1 (pl) |
| DK (1) | DK1963307T3 (pl) |
| EA (1) | EA014354B1 (pl) |
| ES (1) | ES2337187T3 (pl) |
| IL (1) | IL191967A0 (pl) |
| MA (1) | MA30373B1 (pl) |
| NO (1) | NO20082695L (pl) |
| PE (1) | PE20071068A1 (pl) |
| PL (1) | PL1963307T3 (pl) |
| PT (1) | PT1963307E (pl) |
| SI (1) | SI1963307T1 (pl) |
| TW (1) | TW200730498A (pl) |
| WO (1) | WO2007071691A1 (pl) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110160249A1 (en) | 2008-05-23 | 2011-06-30 | Schaab Kevin Murray | 5-lipoxygenase-activating protein inhibitor |
| WO2011000765A1 (en) | 2009-06-29 | 2011-01-06 | Glaxo Group Limited | New medical use |
| JP4785963B2 (ja) | 2009-10-09 | 2011-10-05 | キヤノン株式会社 | 固体撮像装置 |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| WO2015173701A2 (en) | 2014-05-12 | 2015-11-19 | Glaxosmithkline Intellectual Property (No. 2) Limited | Pharmaceutical compositions for treating infectious diseases |
| KR101640756B1 (ko) | 2014-10-28 | 2016-07-19 | 이종찬 | 전동 드릴 장착용 내시경 캡 |
| US20200405728A1 (en) * | 2018-03-01 | 2020-12-31 | Ferox Therapeutics Llc | Methods of preventing and treating hypoglycemia in type 1 and type 2 diabetes patients |
| CN116194114A (zh) | 2020-03-26 | 2023-05-30 | 葛兰素史密斯克莱知识产权发展有限公司 | 用于防止或治疗病毒感染的组织蛋白酶抑制剂 |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9127376D0 (en) | 1991-12-24 | 1992-02-19 | Wellcome Found | Amidino derivatives |
| MX9301943A (es) | 1992-04-02 | 1994-08-31 | Smithkline Beecham Corp | Compuestos. |
| EP0745121B1 (en) | 1992-05-14 | 2007-06-20 | Baylor College Of Medicine | Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy |
| US5364791A (en) | 1992-05-14 | 1994-11-15 | Elisabetta Vegeto | Progesterone receptor having C. terminal hormone binding domain truncations |
| ATE229001T1 (de) | 1994-06-15 | 2002-12-15 | Wellcome Found | Zwischenprodukte verwendbar in der herstellung von enzym-inhibitoren |
| MY117948A (en) | 1997-01-13 | 2004-08-30 | Glaxo Group Ltd | Nitride oxide synthase inhibitors. |
| DE19723722A1 (de) | 1997-05-30 | 1998-12-10 | Schering Ag | Nichtsteroidale Gestagene |
| AU9281298A (en) | 1997-10-01 | 1999-04-23 | Kyowa Hakko Kogyo Co. Ltd. | Benzodioxole derivatives |
| US6506766B1 (en) | 1998-02-13 | 2003-01-14 | Abbott Laboratories | Glucocortiocoid-selective antinflammatory agents |
| ATE270278T1 (de) | 1998-03-14 | 2004-07-15 | Altana Pharma Ag | Phthalazinone pde iii/iv hemmer |
| GB9811599D0 (en) | 1998-05-30 | 1998-07-29 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
| HK1043788A1 (zh) | 1999-05-04 | 2002-09-27 | American Home Products Corporation | 四環黃體酮受體調節劑化合物及方法 |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| CO5180649A1 (es) | 1999-09-01 | 2002-07-30 | Abbott Lab | Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes |
| OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
| AU7576001A (en) | 2000-08-05 | 2002-02-18 | Glaxo Group Ltd | 6.alpha., 9.alpha.-difluoro-17.alpha.-`(2-furanylcarboxyl) oxy]-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent |
| GB0031179D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
| US6484903B2 (en) | 2001-01-09 | 2002-11-26 | Riverwood International Corporation | Carton with an improved dispensing feature in combination with a unique handle |
| GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| ES2288543T3 (es) | 2001-03-08 | 2008-01-16 | Glaxo Group Limited | Agonistas de beta-adrenorreceptores. |
| US7045658B2 (en) | 2001-03-22 | 2006-05-16 | Glaxo Group Limited | Formailide derivatives as beta2-adrenoreceptor agonists |
| CA2458534C (en) | 2001-09-14 | 2011-11-01 | Glaxo Group Limited | Phenethanolamine derivatives for treatment of respiratory diseases |
| US6653323B2 (en) | 2001-11-13 | 2003-11-25 | Theravance, Inc. | Aryl aniline β2 adrenergic receptor agonists |
| WO2003059899A1 (en) | 2002-01-14 | 2003-07-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof |
| AU2003214879B2 (en) | 2002-01-22 | 2008-02-07 | The Regents Of The University Of California | Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof |
| GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
| US7268152B2 (en) | 2002-03-26 | 2007-09-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| WO2003082280A1 (en) | 2002-03-26 | 2003-10-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| DE10215316C1 (de) | 2002-04-02 | 2003-12-18 | Schering Ag | Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer |
| US7282591B2 (en) | 2002-04-11 | 2007-10-16 | Merck & Co., Inc. | 1h-benzo{f}indazol-5-yl derivatives as selective glucocorticoid receptor modulators |
| JP2005523920A (ja) | 2002-04-25 | 2005-08-11 | グラクソ グループ リミテッド | フェネタノールアミン誘導体 |
| US7186864B2 (en) | 2002-05-29 | 2007-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| US7074806B2 (en) | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| SI1521733T1 (sl) | 2002-07-08 | 2014-10-30 | Pfizer Products Inc. | Modulatorji glukokortikoidnega receptorja |
| US6995181B2 (en) | 2002-07-18 | 2006-02-07 | Bristol-Myers Squibb Co. | Modulators of the glucocorticoid receptor and method |
| GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
| ATE403648T1 (de) | 2002-08-21 | 2008-08-15 | Boehringer Ingelheim Pharma | Substituierte dihydrochinoline als glucocorticoid-mmimetika,verfahren zu deren herstellung, pharmazeutische zubereitungen und deren verwendung |
| GB0220730D0 (en) | 2002-09-06 | 2002-10-16 | Glaxo Group Ltd | Medicinal compounds |
| GB0230045D0 (en) | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
| MXPA05002887A (es) | 2002-09-16 | 2005-05-27 | Glaxo Group Ltd | Compuestos de pirazolo[3,4-b]piridina, y su uso como inhibidores de fosfodiesterasa. |
| WO2004026248A2 (en) | 2002-09-20 | 2004-04-01 | Merck & Co., Inc. | Octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators |
| GB0224084D0 (en) * | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| EP1554264B1 (en) | 2002-10-22 | 2007-08-08 | Glaxo Group Limited | Medicinal arylethanolamine compounds |
| EP1554260A1 (en) * | 2002-10-22 | 2005-07-20 | Glaxo Group Limited | Aryloxyalkylamine derivatives as h3 receptor ligands |
| DK1556342T3 (da) | 2002-10-28 | 2008-07-21 | Glaxo Group Ltd | Phenethanolaminderivat til behandling af respiratoriske sygdomme |
| GB0225030D0 (en) | 2002-10-28 | 2002-12-04 | Glaxo Group Ltd | Medicinal compounds |
| GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| GB0225535D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| GB0308333D0 (en) | 2003-04-10 | 2003-05-14 | Glaxo Group Ltd | Novel compounds |
| TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
| AR049384A1 (es) | 2004-05-24 | 2006-07-26 | Glaxo Group Ltd | Derivados de purina |
| WO2006000401A1 (en) | 2004-06-28 | 2006-01-05 | Glaxo Group Limited | Substituted oxazines as glucocorticoid receptor modulators |
| WO2006000398A1 (en) | 2004-06-28 | 2006-01-05 | Glaxo Group Limited | 2,3-benzoxazin derivatives as non-steroidal glucocorticoid receptor modulators |
| GB0418045D0 (en) | 2004-08-12 | 2004-09-15 | Glaxo Group Ltd | Compounds |
| US7465795B2 (en) * | 2005-12-20 | 2008-12-16 | Astrazeneca Ab | Compounds and uses thereof |
| KR20090007604A (ko) | 2006-04-20 | 2009-01-19 | 글락소 그룹 리미티드 | 히스타민 ｈ１ 및 ｈ３ 길항제로서의 2―치환된 4―벤질프탈라지논 유도체 |
-
2006
- 2006-12-18 PE PE2006001620A patent/PE20071068A1/es not_active Application Discontinuation
- 2006-12-18 AR ARP060105590A patent/AR058109A1/es not_active Application Discontinuation
- 2006-12-18 TW TW095147457A patent/TW200730498A/zh unknown
- 2006-12-19 US US12/158,185 patent/US7989629B2/en not_active Expired - Fee Related
- 2006-12-19 PL PL06841477T patent/PL1963307T3/pl unknown
- 2006-12-19 EA EA200801342A patent/EA014354B1/ru not_active IP Right Cessation
- 2006-12-19 JP JP2008546432A patent/JP4445570B2/ja not_active Expired - Fee Related
- 2006-12-19 DE DE602006010737T patent/DE602006010737D1/de active Active
- 2006-12-19 EP EP09176715A patent/EP2157087A1/en not_active Withdrawn
- 2006-12-19 ES ES06841477T patent/ES2337187T3/es active Active
- 2006-12-19 CA CA002634391A patent/CA2634391A1/en not_active Abandoned
- 2006-12-19 EP EP06841477A patent/EP1963307B1/en active Active
- 2006-12-19 PT PT06841477T patent/PT1963307E/pt unknown
- 2006-12-19 AT AT06841477T patent/ATE449769T1/de active
- 2006-12-19 WO PCT/EP2006/069943 patent/WO2007071691A1/en not_active Ceased
- 2006-12-19 BR BRPI0620218-7A patent/BRPI0620218A2/pt not_active IP Right Cessation
- 2006-12-19 AU AU2006328512A patent/AU2006328512B2/en not_active Ceased
- 2006-12-19 KR KR1020087015535A patent/KR20080087102A/ko not_active Ceased
- 2006-12-19 DK DK06841477.0T patent/DK1963307T3/da active
- 2006-12-19 SI SI200630560T patent/SI1963307T1/sl unknown
-
2008
- 2008-06-05 IL IL191967A patent/IL191967A0/en unknown
- 2008-06-11 MA MA31023A patent/MA30373B1/fr unknown
- 2008-06-11 NO NO20082695A patent/NO20082695L/no not_active Application Discontinuation
- 2008-06-20 CR CR10102A patent/CR10102A/es not_active Application Discontinuation
-
2009
- 2009-06-12 JP JP2009140796A patent/JP2009235087A/ja active Pending
-
2010
- 2010-02-19 CY CY20101100170T patent/CY1110601T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR058109A1 (es) | 2008-01-23 |
| AU2006328512A1 (en) | 2007-06-28 |
| WO2007071691A1 (en) | 2007-06-28 |
| BRPI0620218A2 (pt) | 2011-11-01 |
| MA30373B1 (fr) | 2009-05-04 |
| PE20071068A1 (es) | 2007-12-13 |
| EA200801342A1 (ru) | 2008-12-30 |
| HK1120265A1 (en) | 2009-03-27 |
| EP1963307B1 (en) | 2009-11-25 |
| AU2006328512B2 (en) | 2011-06-23 |
| US7989629B2 (en) | 2011-08-02 |
| JP4445570B2 (ja) | 2010-04-07 |
| CA2634391A1 (en) | 2007-06-28 |
| IL191967A0 (en) | 2008-12-29 |
| DE602006010737D1 (de) | 2010-01-07 |
| EP1963307A1 (en) | 2008-09-03 |
| JP2009235087A (ja) | 2009-10-15 |
| ES2337187T3 (es) | 2010-04-21 |
| ATE449769T1 (de) | 2009-12-15 |
| EA014354B1 (ru) | 2010-10-29 |
| DK1963307T3 (da) | 2010-04-06 |
| SI1963307T1 (sl) | 2010-03-31 |
| CR10102A (es) | 2008-09-22 |
| JP2009520001A (ja) | 2009-05-21 |
| CY1110601T1 (el) | 2015-04-29 |
| TW200730498A (en) | 2007-08-16 |
| PL1963307T3 (pl) | 2010-05-31 |
| EP2157087A1 (en) | 2010-02-24 |
| US20080312280A1 (en) | 2008-12-18 |
| PT1963307E (pt) | 2010-03-03 |
| KR20080087102A (ko) | 2008-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20082695L (no) | 3-(4-{[4-(4-{[3-(3,3-dimetyl-1-piperidinyl)propyl]oksy}fenyl)-1-piperidinyl]-karbonyl}-1-naftalenyl)propan- eller propensyre som H1 og H3 reseptorantagonister for behandling av betennelser og/eller allergiske lidelser | |
| NO20074592L (no) | Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister | |
| NO20063382L (no) | Nye kinolinderivater | |
| NO20082000L (no) | Pyrimidinamidforbindelser som PGDS-inhibitorer | |
| NO20084005L (no) | Aminderivater | |
| NO20063761L (no) | Sulfonamidderivater for behandling av sykdommer | |
| NO20072978L (no) | Nye betuinderivater, preparat derav og anvendelse derav | |
| NO20071577L (no) | Bifenyloksyiddiksyrederivater for behandling av luftveissykdommer | |
| NO20090327L (no) | Nye forbindelser 384 | |
| NO20090328L (no) | Nye forbindelser 385 | |
| NO20080408L (no) | Azaindazolforbindelser og anvendelse derav | |
| WO2009006404A3 (en) | Heterocyclic compounds useful as raf kinase inhibitors | |
| NO20085064L (no) | 4,5-difenyl-pyrimidinyl-oksy eller -merkaptosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter | |
| BRPI0409109A (pt) | novos compostos | |
| WO2006072599A3 (en) | Androstane 17-alpha carbonate derivatives for use in the treatment of allergic and inflammatory conditions | |
| NO20084328L (no) | Nye forbindelser | |
| ATE411280T1 (de) | Phenoxyessigsäure-derivate zur behandlung von störungen der atemwege | |
| NO20085169L (no) | Krystallinske solvater og komplekser av (1S)-1,5-anhydro-L-C- (3-((fenyl)metyl)fenyl)-D-glucitol derivater med aminosyrer som SGLT2-inhibitorer for behandling av diabetes | |
| DE602006002366D1 (de) | Androstan-17-alpha-carbonat zur verwendung bei der behandlung entzündlicher und allergischer zustände | |
| WO2008130320A3 (en) | Novel n- (8-heteroaryltetrahydronaphtalene-2yl) or n- (5- heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain | |
| NO20085066L (no) | 4,5-difenyl-pyrimidinyl-aminosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter | |
| BRPI0507877A (pt) | derivados de formamida, composição farmacêutica, uso dos mesmos e combinação | |
| NO20084363L (no) | 2-Substituerte 4-benzylftalazinonderivater som histamin H1- og H3-antagonister | |
| NO20080445L (no) | Nye azetidinderivater som neurokininreseptorantagonister for behandling av gastrointestinale sykdommer | |
| DE60335404D1 (de) | Verwendung von 4-aminochinolin-verbindungen zur behandlung entzündlicher erkrankungen des auges |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |